
Johnson & Johnson (JNJ) really does not require an introduction as the well-run giant continues to deliver on steady returns for long-term investors. A strong multi-year momentum run made that shares doubled over the past five years or so, but shares have recently dropped $20 from the high of nearly $150 per share.
The question is if this drop warrants the decision to buy the dip already, following the release of the first quarter results. While the company remains a core position of mine, the size of the position has been cut quite bit late in 2017, following too strong momentum, in my opinion. Appeal is luring at these levels, although I am waiting for a slightly larger dip before adding again.
READ FULL ARTICLE HERE

